Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy

Brachytherapy

Volumn 10, Issue 1, 2011, Pages 44-50

  Wilder, Richard B ^a   Barme, Greg A ^a   Gilbert, Ronald F ^a   Holevas, Richard E ^a   Kobashi, Luis I ^a   Reed, Richard R ^a   Solomon, Ronald S ^a   Walter, Nancy L ^a   Chittenden, Lucy ^a   Mesa, Albert V ^a   Agustin, Jeffrey K ^a   Lizarde, Jessica ^a   Macedo, Jorge C ^a   Ravera, John ^a   Tokita, Kenneth M ^a  

^a Cancer Center of Irvine   (United States)

Author keywords

Hylaform; Quality of life; Radiotherapy

Indexed keywords

HYALURONIC ACID;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL TRACT; GEL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; GASTROINTESTINAL TRACT; GELS; GOLD RADIOISOTOPES; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RECTUM; VISCOSUPPLEMENTS;

EID: 78651429275     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.12.005     Document Type: Article

References (56)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006, 7:355-362.
3. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998, 41:501-510.
4. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007, 10:82-86.
5. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999, 85:2460-2468.
6. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55:241-249.
7. Al-Salihi O., Mitra A., Payne H. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis 2006, 9:370-373.
8. Fang F.M., Wang Y.M., Wang C.J., et al. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol 2008, 38:474-479.
9. Kotte A.N., Hofman P., Lagendijk J.J., et al. Intrafraction motion of the prostate during external-beam radiation therapy: Analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007, 69:419-425.
10. Mansson Haska T., Honore H., Muren L.P., et al. Intrafraction changes of prostate position and geometrical errors studied by continuous electronic portal imaging. Acta Oncol 2008, 47:1351-1357.
11. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 2007, 84:114-120.
12. Pieters B.R., van de Kamer J.B., van Herten Y.R., et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008, 88:46-52.
13. Lips I.M., Dehnad H., van Gils C.H., et al. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: Acute and late toxicity in 331 patients. Radiat Oncol 2008, 3:15.
14. Soumarova R., Homola L., Perkova H., et al. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: Comparison of acute toxicity. Tumori 2007, 93:37-44.
15. Hallen L., Dahlqvist A. Cross-linked hyaluronan for augmentation of the posterior pharyngeal wall: An experimental study in rats. Scand J Plast Reconstr Surg Hand Surg 2002, 36:197-201.
16. Prada P.J., Fernandez J., Martinez A.A., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:95-102.
17. Prada P.J., Gonzalez H., Menendez C., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8:210-217.
18. Wilder R.B., Barme G.A., Gilbert R.F., et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:824-830.
19. Goffinet D.R., Martinez A., Freiha F., et al. 125Iodine prostate implants for recurrent carcinomas after external beam irradiation: Preliminary results. Cancer 1980, 45:2717-2724.
20. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002, 167:2443-2447.
21. Thompson A., Fox C., Foroudi F., et al. Planning and implementing an implanted fiducial programme for prostate cancer radiation therapy. J Med Imaging Radiat Oncol 2008, 52:419-424.
22. Vetterli D., Thalmann S., Behrensmeier F., et al. Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode. Radiother Oncol 2006, 79:101-108.
23. Monheit G.D. Hylaform: A new hyaluronic acid filler. Facial Plast Surg 2004, 20:153-155.
24. Manna F., Dentini M., Desideri P., et al. Comparative chemical evaluation of two commercially available derivatives of hyaluronic acid (hylaform from rooster combs and restylane from streptococcus) used for soft tissue augmentation. J Eur Acad Dermatol Venereol 1999, 13:183-192.
25. Kiffer J.D., Schumer W.A., Mantle C.A., et al. Impact of oedema on implant geometry and dosimetry for temporary high dose rate brachytherapy of the prostate. Australas Radiol 2003, 47:172-176.
26. Roberts T, Roach M, 3rd. The evolving role of pelvic radiation therapy. Semin Radiat Oncol 2003;13:109-120.
27. Hsu A., Pawlicki T., Luxton G., et al. A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes. Int J Radiat Oncol Biol Phys 2007, 68:898-902.
28. Muanza T.M., Albert P.S., Smith S., et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. Int J Radiat Oncol Biol Phys 2005, 62:1316-1321.
29. Cassidy L.D. Basic concepts of statistical analysis for surgical research. J Surg Res 2005, 128:199-206.
30. Bachand F., Martin A.G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
31. Chen Y.C., Chuang C.K., Hsieh M.L., et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: An experience in Taiwan. Urology 2007, 70:101-105.
32. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006, 66:416-423.
33. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164.
34. Prada P.J., Gonzalez H., Fernandez J., et al. High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer. Clin Transl Oncol 2008, 10:415-421.
35. Marzi S., Arcangeli G., Saracino B., et al. Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:41-49.
36. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:1297-1308.
37. Adams M.E., Lussier A.J., Peyron J.G. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf 2000, 23:115-130.
38. Christensen L., Breiting V., Janssen M., et al. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 2005, 29:34-48.
39. Christensen L. Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatol Surg 2007, 33(Suppl. 2):S168-175.
40. Micheels P. Human anti-hyaluronic acid antibodies: Is it possible? Dermatol Surg 2001, 27:185-191.
41. Monheit G.D. Hyaluronic acid fillers: Hylaform and Captique. Facial Plast Surg Clin North Am 2007, 15:77-84. vii.
42. Carruthers A., Carruthers J. Non-animal-based hyaluronic acid fillers: Scientific and technical considerations. Plast Reconstr Surg 2007, 120:33S-40S.
43. Fernandez-Acenero M.J., Zamora E., Borbujo J. Granulomatous foreign body reaction against hyaluronic acid: Report of a case after lip augmentation. Dermatol Surg 2003, 29:1225-1226.
44. Lowe N.J., Maxwell C.A., Lowe P., et al. Hyaluronic acid skin fillers: Adverse reactions and skin testing. J Am Acad Dermatol 2001, 45:930-933.
45. Larsen N.E., Leshchiner E.A., Parent E.G., et al. Hylan gel composition for percutaneous embolization. J Biomed Mater Res 1991, 25:699-710.
46. Ben-Yosef R., Paz A., Levy Y., et al. A novel device for protecting rectum during prostate cancer irradiation: In vivo data on a large mammal model. J Urol 2009, 181:1401-1406.
47. Volpi N., Schiller J., Stern R., et al. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem 2009, 16:1718-1745.
48. Simone N.L., Menard C., Soule B.P., et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys 2008, 70:90-95.
49. Kouloulias V.E., Kouvaris J.R., Kokakis J.D., et al. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: A retrospective analysis. Int J Radiat Oncol Biol Phys 2004, 59:1148-1156.
50. Dziuk T., Senzer N. Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy. Semin Oncol 2003, 30:49-57.
51. Kouloulias V.E., Kouvaris J.R., Pissakas G., et al. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: Topical intrarectal versus subcutaneous application. Int J Radiat Oncol Biol Phys 2005, 62:486-493.
52. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905.
53. Guedea F., Ferrer M., Pera J., et al. Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: The Catalan Institute of Oncology/Bellvitge Hospital experience. Clin Transl Oncol 2009, 11:470-478.
54. Kupelian P.A., Reddy C.A., Klein E.A., et al. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001, 51:988-993.
55. Valdagni R., Rancati T., Fiorino C., et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 2008, 71:1065-1073.
56. Heemsbergen W.D., Peeters S.T., Koper P.C., et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: Consequential late damage. Int J Radiat Oncol Biol Phys 2006, 66:3-10.